Novartis Reports Sustained 144-Week Phase III Pelabresib Effects
Novartis says Phase III data show sustained effects in first-line JAK inhibitor-naïve myelofibrosis patients through 144 weeks.
Novartis says Phase III data show sustained effects in first-line JAK inhibitor-naïve myelofibrosis patients through 144 weeks.